Chotetawan Tanavalee

Chotetawan Tanavalee

Auto-generated profile, based on publicly available information

Chotetawan Tanavalee

Biologics for Knee Osteoarthritis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Clinical Spine Surgery
Verified
Journal Article
Closed access
CTChotetawan Tanavalee
Chotetawan Tanavalee
PLPanya Luksanapruksa
Panya Luksanapruksa
WSWeerasak Singhatanadgige
Weerasak Singhatanadgige
Microsoft Excel (MS Excel) is a commonly used program for data collection and statistical analysis in biomedical research. However, this program has many limitations, including fewer functions that can be used for analysis and a limited number of total cells compared with dedicated statistical programs. MS Excel cannot complete analyses with blank cells, and cells must be selected manually for analysis. In addition, it requires multiple steps of data transformation and formulas to plot survival analysis graphs, among others. The Megastat add-on program, which will be supported by MS Excel 2016 soon, would eliminate some limitations of using statistic formulas within MS Excel.

27 March 2023 in The Journal of Knee Surgery
Verified
Journal Article
Closed access
PDF file
CCChayut Chaiperm
Chayut Chaiperm
CTChotetawan Tanavalee
Chotetawan Tanavalee
WKWirinaree Kampitak
Wirinaree Kampitak
CAChavarin Amarase
Chavarin Amarase
SNSrihatach Ngarmukos
Srihatach Ngarmukos
ATAree Tanavalee
Aree Tanavalee
A continuous adductor canal block (cACB) for pain control in total knee arthroplasty (TKA) is always performed by an anesthesiologist. A surgeon-performed cACB during surgery is somewhat questionable in terms of feasibility, reproducibility, and efficacy. This study was divided into two phases. In Phase 1 study, an experimental dissection of 16 cadaveric knees to expose the saphenous nerve and related muscles around the adductor canal was conducted. The extent of dye after injection via a catheter inserted into the adductor canal at the time of TKA was evaluated. In Phase II, a randomized controlled trial study comparing clinical outcomes between surgeon-performed (Group 1) and anesthesiologist-performed cACB (Group 2) during TKA in 63 patients was evaluated. The visual analogue scale (VAS) at rest and during movement at several time points and functional outcomes during hospitalization were compared. The Phase I study demonstrated surgeon-performed cACB during surgery feasible and reproducible with consistent dye extension into the adductor canal after injection via a catheter. In the Phase II study, 29 patients of Group 1 and 30 patients of Group 2 completed the evaluation with no differences in baseline parameters. The VAS during movement at 24 and 36 hours, quadriceps strength, time up and go test, and knee motion at different time points, and total morphine consumption showed no differences between both groups. There were no procedure-related complications. The surgeon-performed cACB during surgery was feasible and reproducible with similar VAS scores and functional outcomes during hospitalization to anesthesiologist cACB. Level of evidence is Level I, prospective randomized trial.

1 December 2024 in Hip & Pelvis
Verified
Journal Article
Open access
PDF file
CVChutikant Vichainarong
Chutikant Vichainarong
WKWirinaree Kampitak
Wirinaree Kampitak
SNSrihatach Ngarmukos
Srihatach Ngarmukos
ATAree Tanavalee
Aree Tanavalee
CTChotetawan Tanavalee
Chotetawan Tanavalee
PJPongkwan Jinaworn
Pongkwan Jinaworn
Chutikant Vichainarong, MD, Wirinaree Kampitak, MD, Srihatach Ngarmukos, MD, Aree Tanavalee, MD, Chotetawan Tanavalee, MD, Pongkwan Jinaworn, MD. Hip Pelvis 2024;36:290-301. https://doi.org/10.5371/hp.2024.36.4.290

6 December 2024 in Medicine
Verified
Journal Article
Open access
NJNonn Jaruthien
Nonn Jaruthien
ATAree Tanavalee
Aree Tanavalee
SNSrihatach Ngarmukos
Srihatach Ngarmukos
CTChotetawan Tanavalee
Chotetawan Tanavalee
CAChavarin Amarase
Chavarin Amarase
PSPakpoom Somrak
Pakpoom Somrak
Background: Several studies have proved that diacerein effectively treats knee osteoarthritis (OA). All studies used branded diacerein. Recently, generic diacerein has been available in several countries, with limited studies comparing the efficacy of generic and branded diacerein for knee OA treatment. Methods: Among 200 eligible patients, 94 were randomized to take a daily 50 mg of generic diacerein (Diaceric®); group A or branded diacerein (Artrodar®); group B for treating mild to moderate knee OA. All patients were assigned 5-visit assessments and followed until 24 weeks. The primary outcome was a visual analog scale (VAS) on the motion. The secondary outcomes were 2 patient-report outcome measures (PROMs): the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index and the Short Form-12 (SF-12), as well as 3 performance-based measures (PBMs): 5-time sit to stand test (5 × SST), the time up and go test (TUGT), and the 3-minute walk test (3MWT). Results: There were 47 patients in group A and 47 in group B, with no patients lost for FU. Among all patients, 79.8% were female with a mean age of 63.2 years in group A and 64.8 years in group B. The Kellgren and Lawrence (KL) grade II was the most common in both groups. There were no differences in all demographic data. At 24-week follow-up (FU), both groups had significantly improved VAS, with a 12-week earlier improvement in the branded diacerein. In addition, the PBMs, including 5 × SST and 3MWT, significantly improved from 12-week FU in both groups, with insignificantly improved WOMAC and SF-12 and no serious adverse events in either group. Conclusion: After a 24-week FU, the generic diacerein had similar efficacy as the branded diacerein in significantly improving VAS and PBMs: 5 × SST and 3MWT. However, the latter had a faster statistically improved VAS than the former.


26 October 2024 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
ASAmmarin Suwan
Ammarin Suwan
CTChotetawan Tanavalee
Chotetawan Tanavalee
KPKrasean Panyakhamlerd
Krasean Panyakhamlerd
SNSrihatach Ngarmukos
Srihatach Ngarmukos
SCSuchanant Chavaengkiat
Suchanant Chavaengkiat
TBThanapob Bumphenkiatikul
Thanapob Bumphenkiatikul
Background: Osteoporosis has been recognized as a significant health issue in Thailand. Pharmacological interventions are important way to prevent fracture. However, one of the main challenges in selecting a medication is high cost, particularly for brand-name drugs. Data on generic bisphosphonate use in Thai are still lacking. Therefore, our study aimed to assess the efficacy and safety of generic risedronate in postmenopausal Thai women with osteoporosis. Methods: This prospective study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, from December 2022 to January 2024. Serum C-terminal cross-linking telopeptide of type I collagen (CTX) and procollagen type I N-propeptide (P1NP) were measured at baseline. All participants subsequently received 35 milligrams of oral risedronate once weekly for 52 weeks. Serum CTX and P1NP were remeasured at different time points. BMD was reevaluated at 52 weeks after risedronate treatment initiation. Results: A total of 80 participants were included. The mean age was 65.2 ± 6.6 years. The mean body mass index (BMI) was 23.45 ± 3.49 kg/m2. The median (IQR) serum CTX level at 12 weeks was significantly lower than that at baseline (0.28 (0.16–0.46) ng/mL versus 0.44 (0.26–0.64) ng/mL, respectively; p value < 0.01). The suppression of serum CTX was confirmed at 52 weeks after treatment initiation. Compared with those at baseline, the serum P1NP levels were significantly lower at 24 weeks after treatment initiation (30.33 (19.19–39.58) ng/mL versus 41.90 (30.33–68.67) ng/mL, respectively; p value < 0.01). In terms of the BMD assessment at 52 weeks, significant improvements were observed in both areal BMD (g/cm2) and T scores at all measured sites compared with baseline. The lumbar spine, femoral neck, and total hip BMD increased from baseline by 4.76%, 3.84% and 4.54%, respectively. Conclusion: Postmenopausal women with osteoporosis who were treated with generic risedronate demonstrated significant suppression of the bone remodelling process at 3, 6, and 12 months after treatment initiation. Additionally, significant improvements in the lumbar spine, femoral neck, and total hip BMD were observed at 12 months of therapy. These findings suggest that generic risedronate could be considered a reasonable and interesting option for treating postmenopausal women with osteoporosis in Thailand.